Halo nevus, rather than vitiligo, is a typical dermatologic finding of turner's syndrome: Clinical, genetic, and immunogenetic study in 72 patients

Valeria Brazzelli, Daniela Larizza, Miriam Martinetti, Sara Martinoli, Valeria Calcaterra, Annalisa De Silvestri, Roberta Pandolfi, Giovanni Borroni

Research output: Contribution to journalArticle

Abstract

Turner's syndrome (TS) is a genetic disorder caused by numeric and/or structural abnormalities of the X chromosome; it is characterized by short stature, gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and lymphedema at birth. TS has been associated with several cutaneous abnormalities including an increased frequency of pigmented nevi, but few reports consider nevi in detail. Halo nevus (HN) is clinically defined as a melanocytic nevus surrounded by a halo of depigmentation. Vitiligo, a dermatologic disorder characterized by the presence of depigmented patches on the skin, has been described in the list of cutaneous findings associated with TS. The aim of this study was to determine the prevalence of HN and vitiligo in TS and to evaluate if a correlation between major histocompatability complex genes, karyotype, autoimmunity, therapies, and the presence of HN exists. Of the 72 patients with TS examined, 13 had HN, a prevalence of 18.05%, which was significantly higher than in our control group (1%; P=.000001). On the contrary, only 2 patients with TS (2.77%, P=not significant) had vitiligo. By comparing the distribution of HLA class I alleles between patients with TS who did (13 of 72) and did not (59 of 72) have HN, we observed a significantly higher frequency of HLA-Cw6 in patients with TS and HN than in those without HN (26.92% vs 6.78%, respectively; P=.0067; odds ratio=5.06). The study of HLA class II genomic polymorphisms showed that the DRB1*0701 and DQB1*02 alleles for patients with TS and HN were overrepresented when compared with those without HN (34.61% vs 11.86%, respectively, P=.0078, odds ratio=3.93; and 34.61% vs 19.49%, respectively, P=.1386, odds ratio=2.19). In conclusion, this study is the first to demonstrate an increased prevalence of HN for patients with TS. Furthermore, the data suggest that a HN putative susceptibility gene in TS is located close to the HLA-C locus.

Original languageEnglish
Pages (from-to)354-358
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume51
Issue number3
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Halo Nevi
Immunogenetics
Vitiligo
Turner Syndrome
Pigmented Nevus
Odds Ratio
Alleles
Skin Abnormalities
HLA-C Antigens
Gonadal Dysgenesis
Skin
Inborn Genetic Diseases
Lymphedema
Nevus
X Chromosome
Autoimmunity
Karyotype

Keywords

  • GH
  • growth hormone
  • halo nevus
  • HN
  • odds ratio
  • OR
  • organ-specific autoantibodies
  • OSA
  • TS
  • Turner's syndrome

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{d60c8eea4b2f4659be3c68d82e14100b,
title = "Halo nevus, rather than vitiligo, is a typical dermatologic finding of turner's syndrome: Clinical, genetic, and immunogenetic study in 72 patients",
abstract = "Turner's syndrome (TS) is a genetic disorder caused by numeric and/or structural abnormalities of the X chromosome; it is characterized by short stature, gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and lymphedema at birth. TS has been associated with several cutaneous abnormalities including an increased frequency of pigmented nevi, but few reports consider nevi in detail. Halo nevus (HN) is clinically defined as a melanocytic nevus surrounded by a halo of depigmentation. Vitiligo, a dermatologic disorder characterized by the presence of depigmented patches on the skin, has been described in the list of cutaneous findings associated with TS. The aim of this study was to determine the prevalence of HN and vitiligo in TS and to evaluate if a correlation between major histocompatability complex genes, karyotype, autoimmunity, therapies, and the presence of HN exists. Of the 72 patients with TS examined, 13 had HN, a prevalence of 18.05{\%}, which was significantly higher than in our control group (1{\%}; P=.000001). On the contrary, only 2 patients with TS (2.77{\%}, P=not significant) had vitiligo. By comparing the distribution of HLA class I alleles between patients with TS who did (13 of 72) and did not (59 of 72) have HN, we observed a significantly higher frequency of HLA-Cw6 in patients with TS and HN than in those without HN (26.92{\%} vs 6.78{\%}, respectively; P=.0067; odds ratio=5.06). The study of HLA class II genomic polymorphisms showed that the DRB1*0701 and DQB1*02 alleles for patients with TS and HN were overrepresented when compared with those without HN (34.61{\%} vs 11.86{\%}, respectively, P=.0078, odds ratio=3.93; and 34.61{\%} vs 19.49{\%}, respectively, P=.1386, odds ratio=2.19). In conclusion, this study is the first to demonstrate an increased prevalence of HN for patients with TS. Furthermore, the data suggest that a HN putative susceptibility gene in TS is located close to the HLA-C locus.",
keywords = "GH, growth hormone, halo nevus, HN, odds ratio, OR, organ-specific autoantibodies, OSA, TS, Turner's syndrome",
author = "Valeria Brazzelli and Daniela Larizza and Miriam Martinetti and Sara Martinoli and Valeria Calcaterra and {De Silvestri}, Annalisa and Roberta Pandolfi and Giovanni Borroni",
year = "2004",
month = "9",
doi = "10.1016/j.jaad.2003.11.082",
language = "English",
volume = "51",
pages = "354--358",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Halo nevus, rather than vitiligo, is a typical dermatologic finding of turner's syndrome

T2 - Clinical, genetic, and immunogenetic study in 72 patients

AU - Brazzelli, Valeria

AU - Larizza, Daniela

AU - Martinetti, Miriam

AU - Martinoli, Sara

AU - Calcaterra, Valeria

AU - De Silvestri, Annalisa

AU - Pandolfi, Roberta

AU - Borroni, Giovanni

PY - 2004/9

Y1 - 2004/9

N2 - Turner's syndrome (TS) is a genetic disorder caused by numeric and/or structural abnormalities of the X chromosome; it is characterized by short stature, gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and lymphedema at birth. TS has been associated with several cutaneous abnormalities including an increased frequency of pigmented nevi, but few reports consider nevi in detail. Halo nevus (HN) is clinically defined as a melanocytic nevus surrounded by a halo of depigmentation. Vitiligo, a dermatologic disorder characterized by the presence of depigmented patches on the skin, has been described in the list of cutaneous findings associated with TS. The aim of this study was to determine the prevalence of HN and vitiligo in TS and to evaluate if a correlation between major histocompatability complex genes, karyotype, autoimmunity, therapies, and the presence of HN exists. Of the 72 patients with TS examined, 13 had HN, a prevalence of 18.05%, which was significantly higher than in our control group (1%; P=.000001). On the contrary, only 2 patients with TS (2.77%, P=not significant) had vitiligo. By comparing the distribution of HLA class I alleles between patients with TS who did (13 of 72) and did not (59 of 72) have HN, we observed a significantly higher frequency of HLA-Cw6 in patients with TS and HN than in those without HN (26.92% vs 6.78%, respectively; P=.0067; odds ratio=5.06). The study of HLA class II genomic polymorphisms showed that the DRB1*0701 and DQB1*02 alleles for patients with TS and HN were overrepresented when compared with those without HN (34.61% vs 11.86%, respectively, P=.0078, odds ratio=3.93; and 34.61% vs 19.49%, respectively, P=.1386, odds ratio=2.19). In conclusion, this study is the first to demonstrate an increased prevalence of HN for patients with TS. Furthermore, the data suggest that a HN putative susceptibility gene in TS is located close to the HLA-C locus.

AB - Turner's syndrome (TS) is a genetic disorder caused by numeric and/or structural abnormalities of the X chromosome; it is characterized by short stature, gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and lymphedema at birth. TS has been associated with several cutaneous abnormalities including an increased frequency of pigmented nevi, but few reports consider nevi in detail. Halo nevus (HN) is clinically defined as a melanocytic nevus surrounded by a halo of depigmentation. Vitiligo, a dermatologic disorder characterized by the presence of depigmented patches on the skin, has been described in the list of cutaneous findings associated with TS. The aim of this study was to determine the prevalence of HN and vitiligo in TS and to evaluate if a correlation between major histocompatability complex genes, karyotype, autoimmunity, therapies, and the presence of HN exists. Of the 72 patients with TS examined, 13 had HN, a prevalence of 18.05%, which was significantly higher than in our control group (1%; P=.000001). On the contrary, only 2 patients with TS (2.77%, P=not significant) had vitiligo. By comparing the distribution of HLA class I alleles between patients with TS who did (13 of 72) and did not (59 of 72) have HN, we observed a significantly higher frequency of HLA-Cw6 in patients with TS and HN than in those without HN (26.92% vs 6.78%, respectively; P=.0067; odds ratio=5.06). The study of HLA class II genomic polymorphisms showed that the DRB1*0701 and DQB1*02 alleles for patients with TS and HN were overrepresented when compared with those without HN (34.61% vs 11.86%, respectively, P=.0078, odds ratio=3.93; and 34.61% vs 19.49%, respectively, P=.1386, odds ratio=2.19). In conclusion, this study is the first to demonstrate an increased prevalence of HN for patients with TS. Furthermore, the data suggest that a HN putative susceptibility gene in TS is located close to the HLA-C locus.

KW - GH

KW - growth hormone

KW - halo nevus

KW - HN

KW - odds ratio

KW - OR

KW - organ-specific autoantibodies

KW - OSA

KW - TS

KW - Turner's syndrome

UR - http://www.scopus.com/inward/record.url?scp=4444270632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444270632&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2003.11.082

DO - 10.1016/j.jaad.2003.11.082

M3 - Article

C2 - 15337976

AN - SCOPUS:4444270632

VL - 51

SP - 354

EP - 358

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -